MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma

In the present study we analyzed immunohistochemical expression of MAGE-A 3/4 and NY-ESO-1 in 55 samples of esophageal squamous cell carcinomas (ESCC) and their respective lymph node metastases. To our knowledge this is the first study to assess and compare the expression of these antigens in ESCC lymph node metastases. Fifty (90.9%) primary ESCC were positive for MAGE-A 3/4 and 53 (96.6%) were positive for NY-ESO-1. MAGE-A 3/4 was expressed in all lymph node metastases and the intensity of expression was high in a majority of cases. NY-ESO-1 was negative in 2 (7.1%) lymph nodes metastases, while the reaction was predominantly moderate in the positive group. In primary tumors MAGE-A 3/4 showed a significantly higher intensity of expression compared to NY-ESO-1 (P=0.047), while in lymph node metastases the intensity of expression was not significantly different (P=0.387). Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression. Intensity of MAGE-A 3/4 (P=0.461) and NY-ESO-1 (P=0.414) expression in primary tumors was not significantly different compared to the expression in their respective lymph nodes metastases. Expression of MAGE-A 3/4 in primary tumors showed significant positive correlation with primary tumor expression of NY-ESO-1 (P=0.021) but no significant correlation with the expression of MAGE-A 3/4 in lymph node metastases (P=0.056). Expression of NY-ESO-1 in primary tumors showed significant positive correlation with the expression of NY-ESO-1 in lymph node metastases (P=0.001) and significant negative correlation with patients’ age (P<0.001). Expression of MAGE-A 3/4 and NY-ESO-1 in primary tumors and lymph node metastases showed no significant correlation with prognostic parameters such as tumor grade and TNM stage (P>0.05). We have shown different levels of MAGE-A 3/4 and NY-ESO-1 expression in almost all specimens of primary tumor and lymph node metastases, suggesting that ESCC may be possible target of immunotherapy and anti-tumor vaccination. High levels of expression in lymph node metastases indicate possible clinical benefit of postoperative vaccine with MAGE-A3 and NY-ESO-1 in advanced stage of disease.     

DcR3蛋白在人食管鳞状细胞癌中的表达及临床意义

目的:探讨诱骗受体(Decoy receptor 3,Dc R3)蛋白在人食管鳞状细胞癌中的表达和临床意义。方法:通过免疫组化的方法,在人食管鳞状细胞癌组织和正常食管粘膜组织各112例中检测Dc R3蛋白的表达差异,并分析Dc R3蛋白表达与食管鳞状细胞癌临床病理学特征间的相关性。结果:在组织标本中检测发现,Dc R3蛋白在食管鳞状细胞癌组织中的阳性表达为72.3%,在正常食管粘膜组织中的阳性表达为25.9%。卡方检验分析表明,Dc R3蛋白在食管鳞状细胞癌组织中的阳性表达与食管鳞状细胞癌的临床分级(P=0.002)、淋巴结转移(P0.001)、组织学分级(P=0.01)具有显著相关性,而与患者的年龄(P=0.673)、性别(P=0.378)、抽烟史(P=0.392)、饮酒史(P=0.093)等均无关。Spearman相关性分析检测发现,Dc R3蛋白高表达与高临床分级(r=-0.213,P=0.024)、高组织学分级(r=-0.285,P=0.002)、淋巴结转移(r=-0.568,0.001)呈正相关,而与食管鳞状细胞癌患者的年龄、性别、吸烟史、饮酒史等均无相关性(P0.05)。结论:Dc R3蛋白在食管鳞状细胞癌组织中表达更高,且与食管鳞状细胞癌疾病的进展、转移呈正相关。Dc R3蛋白表达可用来检测食管鳞状细胞癌疾病严重程度。     

β-catenin在食管鳞癌中的异常表达及临床意义

目的探讨β-catenin基因在食管鳞状细胞癌(Esophageal squamous cell carcinoma,ESCC)中的表达及其意义。方法免疫组化法检测65例ESCC及20例因ESCC手术切除的远切端正常食管黏膜组织中β-catenin的表达及定位,分析其与临床病理学参数的关系;RT-PCR检测31例新鲜ESCC及相应的远切断正常食管黏膜组织中β-catenin mRNA的表达。结果免疫组化结果显示:在20例因ESCC手术切除的远切端正常食管黏膜组织中,β-catenin主要位于胞膜;在65例ESCC组织中,β-catenin的胞质积累阳性率为63.1%,胞核积累阳性率为30.8%;β-catenin的胞质/核积累与淋巴结转移相关(P=0.005),但与患者的年龄、性别、肿瘤的分化程度及浸润深度等无关。RT-PCR结果显示:在31例ESCC及相应的远切端正常食管黏膜组织中,均检测到β-catenin mRNA的表达,与相应的远切端正常食管黏膜组织比较,癌组织中β-catenin基因mRNA的表达水平明显升高(P=0.037),其中表达升高的21例,占67.7%,表达无明显差异的8例,占25.8%,表达降低的2例,占6.5%。结论在ESCC中存在β-catenin mRNA表达水平的升高以及β-catenin蛋白的异常胞质/胞核积累,并与淋巴结转移有关。     

Fas 相关死亡结构域蛋白在乳腺癌中表达的临床病理研究

目的:探讨Fas相关死亡结构域蛋白(Fas-associated death domain protein,FADD)在乳腺癌中表达的临床病理学意义。方法:收集乳腺癌病例及相应的临床资料包括随访资料,应用免疫组织化学技术检测乳腺良性病变,有/无淋巴结转移的乳腺癌及配对淋巴结转移灶中FADD的表达,观察分析FADD表达与乳腺癌患者年龄、肿块大小、临床分期、组织学类型和分级、雌孕激素受体水平等临床病理指标间的关系。结果:免疫组化检测结果显示良性乳腺病变组中FADD的阳性表达率(85.1%,40/47)与无淋巴结转移的乳腺癌组(45.8%,38/83),伴有淋巴结转移的乳腺癌组(67.3%72/107)和淋巴结转移灶(45.8%,49/107)组织中FADD阳性表率均有显著性差异(P值分别0.001,=0.022和0.001);此外,伴有淋巴结转移的乳腺癌组中FADD阳性表达率也均与其它三组中FADD阳性表达率之间具有显著性差异(P值分别为0.003,0.001和0.022)。FADD与患者的确诊年龄(P=0.049)和淋巴结转移有显著性相关(P=0.003),与肿瘤大小、临床分期、组织学类型、组织学分级、雌孕激素受体及cerb B-2的表达情况和月经史无明显相关性(P0.05)。生存分析显示FADD阳性表达的患者较FADD阴性患者的生存期更短。结论:FADD与乳腺癌淋巴结转移和预后有关。     

食管鳞状细胞癌中血管生成拟态及MMP-1蛋白的表达

目的 研究人食管鳞状细胞癌(human esophageal squamous cell carcinoma,ESCC)中是否存在血管生成拟态(vasculogenic mimicry,VM)及其与(Matrix metalloproteinase-1,MMP-1)表达的关系,以及MMP-1过表达的临床意义.方法收集118例食管鳞状细胞癌的标本,每例均有完整的临床资料,利用CD31(Platelet endothelial cell adhesion molecule,PECAM-1)和PAS套染观察是否存在VM,对VM组和对照组进行MMP-1染色,分析VM与MMP-1表达的关系及MMP-1表达与临床病理学参数的关系.结果 118例食管鳞状细胞癌组织中有34例(28.81%)存在VM,有VM生成组的MMP-1过表达比例显著高于无VM组,两组之间的差异有统计学意义(P<0.05).有淋巴结转移组的MMP-1过表达的比例显著高于无淋巴结转移组(P<0.05);浸润至深肌层及外膜层的MMP-1过表达的比例显著高于浸润之粘膜层和浅肌层的(P<0.05);临床分期Ⅲ-Ⅳ期的MMP-1蛋白的过表达显著高于临床分期Ⅰ-Ⅱ期的(P<0.05).结论 食管鳞状细胞癌中存在VM,MMP-1的过表达可能促进VM形成;VM的存在和MMP-1过表达共同促进淋巴结转移和肿瘤浸润.     

组织蛋白酶D和nm23基因蛋白在乳腺癌中的表达及与淋巴结转移的关系

采用免疫组织化学 ABC法检测了 43例乳腺癌中的组织蛋白酶 D和 nm 2 3基因蛋白的表达。结果显示组织蛋白酶D在乳腺癌组织中表达阳性率为 76 .7% (33/43)。 43例乳腺癌中 2 5例伴有淋巴结转移 ,18例无淋巴结转移 ,其组织蛋白酶D表达阳性率分别为 92 % (2 3/2 5 )及 5 5 .6 % (10 /18) ,两者之间具有显著性差异 (P<0 .0 1)。 nm 2 3基因蛋白在 43例乳腺癌中阳性率为 72 .1% (31/43)。在有淋巴结转移和无淋巴结转移的乳腺癌中 nm2 3基因蛋白阳性率分别为 6 0 % (15 /2 5 )及80 .9% (16 /18) ,nm2 3基因蛋白的表达与淋巴结转移呈显著负相关 (P<0 .0 5 )。结果提示对乳腺癌根治术后无淋巴结转移 ,但组织蛋白酶 D表达阳性 ,nm2 3基因蛋白表达阴性的患者 ,可能具有潜在的复发和转移倾向 ,应多加关注 ,并密切随访。     

CD40 signal expression in gastric cancer tissue and its correlation with prognosis of gastric cancer patients

CD40 signaling plays a critical role in the survival rate of gastric cancer patients. Tumour samples were collected from 73 patients with who were diagnosed as gastric cancer in general surgery department in the 1st affiliated hospital of Suzhou University between September 2002 and July 2003. All patients had not received radiotherapy and chemotherapy before operation. These patients include 46 male and 27 female. Here we show that CD40 is constitutively expressed in the human gastric carcinoma tissues, and CD40 protein and mRNA positive expression in gastric cancer tissues closely correlated with lymph node metastasis and tumour TNM stage. CD40 positive expression in gastric cancer patients with lymph node metastasis was markedly higher than that in gastric cancer patients without lymph node metastasis. CD40 positive expression in stage III-IV gastric cancer patients was markedly higher than that in stage I-II gastric cancer patients. Moreover, CD40 expression closely correlated with prognosis of gastric cancer patients. Therefore, CD40 was taken as grouping variable, and lymph node metastasis and clinical staging were taken as stratification variables, respectively, further analysis showed that prognosis in gastric cancer patients with lymph node metastasis and CD40 positive expression was markedly worse than that in gastric cancer patients without lymph node metastasis and CD40 negative expression (P = 0.0076). These results suggest that CD40 signaling plays a critical role in the survival of gastric cancer patients.     

乳腺癌中α- 晶状体B 链蛋白表达的临床病理研究

目的:探讨α-晶状体蛋白B链(Alpha-crystallin B chain,CRYAB)在乳腺癌中表达的临床病理学意义。方法:收集乳腺癌病例及相应的临床资料包括随访资料,应用IHC染色方法检测CRYAB在乳腺良性病变(BBD)、无淋巴结转移乳腺癌(NMBC)、有淋巴结转移乳腺癌(MBC)及配对淋巴结转移灶(PMLN)中的表达,分析CRYAB表达与乳腺癌临床病理指标(患者年龄、肿块大小、淋巴结转移情况、临床分期、组织学分型和分级、雌孕激素受体和c-cerb B2表达情况、绝经情况)间及生存状态的关系。结果:CRYAB在对照组BBD组、NMBC组、MBC组、PMLN组的阳性表达率分别为97.9%(46/47)、44.6%(37/83)、13.1%(14/107)、10.8%(11/107),其中BBD组和NMBC组,BBD组、NMBC组分别与MBC组、PMLN组均存在显著性差异。CRYAB表达与淋巴结转移(P0.001)、临床分期(P=0.001)、组织学分级(P=0.037)和雌孕激素受体表达情况(P0.001)有显著相关,无淋巴结转移组的阳性表达率显著高于有淋巴结转移组,临床晚期的阳性表达率低于临床早期,雌孕激素受体阳性病例的阳性表达率显著低于雌孕激素受体阴性病例。生存分析结果显示CRYAB阳性表达的患者生存期比CRYAB阴性表达的患者生存期更长(p=0.037)。结论:CRYAB与乳腺癌的转移、临床分期、生存状态、雌孕激素受体表达有关。     

抑癌基因PTEN 在甲状腺乳头状癌中的表达及临床意义*

目的:通过免疫组织化学方法检测PTEN基因在正常甲状腺组织、甲状腺良性肿瘤组织、甲状腺乳头状癌癌组织中的表达水平并进行比较,探讨其对甲状腺乳头状癌诊断和治疗的意义。方法:采用SP免疫组化方法,用已知阳性组织做阳性对照,以磷酸盐缓冲液(PBS)代替一抗做阴性对照,分别作HE染色和免疫组织化学染色。结果:PTEN蛋白在三组组织中的表达差异具有显著性(P<0.001);正常甲状腺组织、甲状腺良性肿瘤组织中的阳性率分别为100%和82.5%,均显著高于甲状腺癌组织中的45%(P<0.05),即PTEN在甲状腺癌中表达显著降低;PTEN在甲状腺乳头状癌淋巴结转移组和无淋巴结转移组阳性表达率分别为15%和60%,差异有显著性(x2=10.91,P=0.001);PTEN在甲状腺乳头状癌在包膜侵犯组和无侵犯组的阳性表达率分别为25.93%和60.61%,差异有显著性(x2=7.22,P=0.007);PTEN在甲状腺癌淋巴结转移组和包膜侵犯组的阳性表达强度显著低于无淋巴结转移和包膜侵犯组(P<0.01),有统计学意义。结论:PTEN基因表达的降低在甲状腺癌的发生和转移过程中起重要作用。     

细胞周期相关蛋白cyclin D1、p53和p21WAF1/Cip1在食管鳞癌中的表达改变及其病理学意义

食管鳞状细胞癌(Esophageal squamous cell carcinoma, ESCC)是我国常见的恶性肿瘤之一, 虽然临床诊治手段正逐步改进, 但中晚期患者5年生存率仍然很低。目前认为细胞周期调控异常与肿瘤发生发展关系密切, 然而相关周期调节蛋白在食管癌患者中的表达改变、临床意义及其应用价值还没有明确结论。文章应用组织微阵列联合免疫组织化学技术(TMA-IHC), 对148例食管鳞癌组织标本中细胞G₁/S期调控蛋白cyclin D1、p53和p21^WAF1/Cip1的表达进行检测, 分析其与临床病理参数之间的相关性。结果显示, cyclin D1与p53蛋白在食管癌细胞中表达升高, p53表达阳性率与区域淋巴结转移显著相关(P = 0.001)。p21^WAF1/Cip1蛋白在肿瘤组织中表达降低, 且p21WAF1/Cip1表达阴性患者的术后生存时间显著短于表达阳性的患者(P = 0.001)。多因素生存分析显示p21WAF1/Cip1是一个独立的预后因素(相对危险度为0.418, P<0.001)。微阵列比较基因组杂交(array-CGH)检测进一步表明45.4%的食管癌患者存在cyclin D1基因扩增。以上结果提示食管鳞癌中存在细胞周期G1/S期调控异常, p21^WAF1/Cip1蛋白可能是一个有应用价值的预后因子。     

VEGF-A在食管鳞状细胞癌中的表达及临床意义

目的:探讨血管内皮生长因子A(VEGF-A)在食管鳞状细胞癌中的表达及临床意义。方法:收集2009年1月-2010年12月收治的45例食管鳞状细胞癌患者临床资料及病理标本,应用免疫组织化学法检测肿瘤组织VEGF-A表达及微淋巴管密度(MLVD),分析VEGF-A表达与食管鳞癌患者临床病理资料、MLVD及与患者生存期限的关系。结果:1有淋巴结转移的患者VEGF-A表达阳性率为66.67%,明显高于无淋巴结转移患者的38.10%(P0.05);2 VEGF-A阳性食管鳞状细胞癌患者MLVD为(8.35±2.45)明显高于阴性患者的(5.32±1.44),(P0.05);3VEGF-A阳性食管鳞状细胞癌患者3年存活率为41.67%明显低于阴性患者的61.90%(P0.05)。结论:VEGF-A表达在确定早期食管鳞状细胞癌淋巴结转移方面具有一定的应用价值,可以作为评价预后的有效指标。     

食管鳞癌VEGF—C mRNA和CD31表达及其意义

To investigate the expression of vascular endothelial growth factor-C (VEGF-C) mRNA and CD 31 in esophageal squamous cell carcinoma (ESCC) and its promotion of lymphatic metastasis. The expression of VEGF-C mRNA was examined in 43 ESCC by in situ hybridization. Intratumoral microvessel density (MVD) was assessed by immunostaining endothelial cells, using anti-CD31 antibody. The positive rate of VEGF-C mRNA expression was 41.86%. The average rank of MVD was 76.36 +/- 20.30/mm2. VEGF-C mRNA expression correlated significantly with lymph node metastasis, TNM stage and depth of invasion (p < 0.05 or p < 0.01) in statistic, but not with histological grade (differentiation) (p > 0.05). MVD correlated significantly with lymph node metastasis and TNM stage (p < 0.05) in statistic, but not with depth of invasion and histological grade (differentiation) (p > 0.05). MVD was significant higher in the VEGF-C positive tumors than negative tumors (p < 0.05). The present study indicated that VEGF-C might play a role in lympatic metastasis via lymphangiogenesis and angiogenesis in ESCC.     

maspin在食管鳞状细胞癌中的表达及其与微血管密度的关系

目的研究旨在寻找能预测食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)浸润、转移及术后生存率的生物因子。方法采用免疫组织化学ElivisionTM plus法检测100例ESCC和30例正常食管组织中maspin的表达和微血管密度(microvessel density,MVD)情况。结果在正常食管组织和ESCC组织中,maspin的阳性表达率分别为100%和43.0%,差异有显著性(P<0.01);maspin的表达水平与肿瘤的分化程度、浸润深度、淋巴结转移和临床分期有关(全部P<0.01);MVD计数与肿瘤的大小、分化程度、淋巴结转移以及临床分期有关(全部P<0.01);且maspin的表达与MVD计数呈负相关(P<0.01)。结论 maspin的表达和MVD计数与ESCC组织的分化程度、转移和预后等均有关;maspin和MVD联合检测对ESCC的进展及预后判断有重要意义。     

肿瘤淋巴管入侵与无淋巴结转移膀胱癌复发及预后的相关性分析

目的:分析肿瘤淋巴管入侵与无淋巴结转移膀胱癌复发和预后之间的关系。方法:选取临床资料完整的膀胱癌病例72例,分为淋巴结转移组(32例)和无淋巴结转移组(40例)。采用Spearman相关分析探讨淋巴管入侵与膀胱癌复发和预后的相关性,应用Kaplan-Meier法描绘生存曲线,Cox比例危险度模型筛选影响膀胱癌患者预后的因素。结果:在72例膀胱癌组织中,淋巴管入侵的阳性率是48.6%(35/72),淋巴管入侵的阳性率随肿瘤分期和分级增加而显著升高(P0.05);淋巴结转移组的淋巴管入侵阳性率为68.8%(22/32),显著高于无淋巴结转移的32.5%(13/40)。淋巴管入侵与膀胱癌的临床分期、分级、淋巴结转移以及无淋巴结转移膀胱癌复发均显著相关(P0.05)。淋巴管入侵阴性的患者的五年总体生存率显著高于淋巴管入侵阳性者,淋巴管入侵是无淋巴结转移膀胱癌复发和预后不良的危险因素。结论:肿瘤淋巴管入侵与膀胱癌临床分期和淋巴结转移密切相关,并影响膀胱癌患者的总体生存率,可作为无淋巴结转移膀胱癌复发和预后的预测因素。     

High YKL-40 Serum Concentration Is Correlated with Prognosis of Chinese Patients with Breast Cancer

This study aimed to investigate the association between serum YKL-40 and prognosis of breast cancer in a Chinese population. Expression of YKL-40 of 120 Chinese patients with breast cancer and 30 controls (benign breast lesions) was measured in tumor tissue by immunohistochemistry and in serum by ELISA. Differences in YKL-40 positivity grouped by specific patients’ characteristics were compared using Pearson Chi-square test for rates of intratumoral staining, one-way ANOVA with a Bonferroni post-hoc comparison, or two-sample t-test for mean YKL-40 serum concentrations. Factors associated with overall survival were identified by univariate and multivariate cox-regression analyses. YKL-40 was elevated in approximately 75% of Chinese patients with breast cancer. A significantly higher percentage of patients with YKL-40 positive tumors had larger tumor size, higher TNM stage, and/or lymph node metastasis. Significantly higher mean YKL-40 serum concentrations were observed in patient subgroups with invasive lobular carcinoma (P<0.0167), higher TNM stage (P<0.001), and positive lymph node metastasis (P<0.001). The estimated mean survival time of patients with YKL-40 positive tumors was significantly shorter than for patients with YKL-40 negative tumors (55.13 months vs 65.78 months, P = 0.017). Multivariable Cox-regression analysis identified a significant association of overall survival time with YKL-40 serum concentration. Patients with YKL-40 positive tumors had significantly shorter disease free survival times than those with YKL-40 negative tumors. We propose that the potential utility of YKL-40 intratumoral staining or serum concentration as a biomarker for breast cancer is greatest within 5 years of diagnosis.     

卵巢癌中结缔组织生长因子的表达及其临床病理意义

目的:探讨卵巢癌中结缔组织生长因子(CTGF)的表达及其与卵巢癌临床病理特征的关系。方法:采用免疫组化法检测116例卵巢癌和25例正常卵巢组织中CTGF表达,并分析其与卵巢癌临床病理参数的关系。结果:正常卵巢组织及卵巢癌中CTGF的阳性表达率分别96%(24/25)、65%(75/116),卵巢癌中CTGF的阳性表达率显著低于正常卵巢组织(P0.05)。CTGF的表达降低与卵巢癌患者的淋巴结转移、腹膜内转移及对化疗的敏感性显著相关(P0.05);进一步的多因素Logistic回归分析显示CTGF的表达与卵巢癌腹膜转移(P=0.006,OR=4.185,95%CI=1.447-11.352)和淋巴结转移(P0.001,OR=6.336,95%CI=2.563-15.972)均显著相关。结论:卵巢癌中CTGF的表达缺失,是卵巢癌腹膜转移和淋巴结转移的独立影响因素,可能作为预测卵巢癌转移的参考指标。     

Kallistatin在乳腺癌中表达的临床病理意义

目的:探讨Kallistatin在乳腺癌中表达的临床病理意义及预后价值。方法:收集乳腺癌档案蜡块及临床资料,分为无淋巴结转移的原发灶(NMBT),有淋巴结转移的原发灶(PBT)及配对的淋巴结转移灶(PMLN),应用免疫组化技术检测Kallistatin表达,统计学分析。结果:结果显示kallistatin在PBT组的表达高于NMBT组合和PMLN组。kallistatin的表达与组织学类型(P=0.003)、淋巴结状态(P0.001)、临床分期(P=0.002)、雌激素受体(ER)表达(P=0.046)有显著相关性。kallistatin在浸润性小叶癌中的阳性表达率高于浸润性导管癌,在PBT组的阳性表达率显著高于NMBT,临床分期越晚期阳性表达率越高,在ER阳性的病历中表达更高。Kaplan-Meier分析显示,kallistatin的阳性表达是乳腺癌患者无病生存时间短(P=0.008)和总生存时间短(P=0.006)的危险因素。在浸润性乳腺导管癌患者中,kallistatin的阳性表达与生存时间短有关(P=0.026)。还与ER阳性表达患者生存时间较短有关(P=0.010)。结论:Kallistatin在乳腺癌中的表达有较为复杂的临床病理意义,其表达提示预后不良。